| | | April 20, 2022 Welcome to the BRAND NEW Stock Dork Premarket Report, your go-to guide for the day's biggest trading news and hottest premarket stocks. Keep an eye out for our Premarket Reports moving forward and, as always, we invite you to reply to this email with your feedback, suggestions, or comments. It's Wednesday, April 20th. Let's get ready to trade! |
| The Nasdaq gained 2.2%, and the S&P 500 added 1.6% on the day. The Dow advanced 1.5%, while the small-cap Russell 2K rallied 2.0%. Today, futures are wobbly in the premarket, but S&P 500 contracts are currently showing fractional gains less than 0.1%. Dow contracts are showing a 0.2% gain. Netflix [NFLX] - Last Close: $348.61 Netflix's shares are crashing after a weak earnings report. The streaming company reported it lost 200,000 paying subscribers for the first time in its recent history. News of the decline prompted a sharp sell off in shares, and the stock is now on track for its largest single-day loss in nearly a decade. Shares of the company fell through their 52-week low, and are continuing to show declines heading into the open. If you're long-term bullish on Netflix, this could be a buying opportunity. Shares of NFLX are trading actively with a 27.1% decline. Allovir Inc [ALVR] - Last Close: $5.41 Allovir is surging on news of a favorable regulatory decision. The clinical-stage cell therapy company announced that the US Food & Drug Administration has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its lead investigational multi-virus-specific T cell therapy, posoleucel, for the prevention of six viruses commonly impacting high-risk adult and pediatric patients. The FDA designation allows the company to discuss clinical trial design with regulators, as well as clinical trial design and other actions to expedite development and review. News of the RMAT designation is rallying shares of ALVR. Shares are up 19.6% on active trading volume. Windtree Therapeutics [WINT] - Last Close: $0.9999 Clinical data is giving shares of Windtree Therapeutics a premarket boost. The clinical-stage biopharma company reported positive topline data from a Phase-2 study of its istaroxime drug candidate to treat patients in cariogenic shock met its primary endpoint. Windtree's istaroxime produced a favorable difference in systolic blood pressure over a six-hour period following a drug infusion. WINT is trading actively with a 42.0% gain. Clarus Therapeutics Holdings [CRXT] - Last Close: $1.45 Clarus Therapeutics is surging as investors anticipate pivotal drug data. The company announced that it will reveal new data for its jatenzo drug candidate at the Androgen Society's upcoming annual meeting in Orlando, Florida. The company says it will present two abstracts at the conference, which is set for April 23rd. Jatenzo is the first FDA-approved oral softgel for testosterone replacement therapy in adult males with certain types of medical-related testosterone deficiency. CRXT is trading actively with a 23.5% gain. |
| Gainers Borqs Tech [BRQS] >> +13.7% Westwater Resources [WWR] >> +14.7% Toughbuilt Industries [TBLT] >> +11.9% Decliners Rimini Street [RMNI] >> (15.1%) Gulf Resources [GURE] >> (14.6%) Medavail Holdings [MDVL] >> (10.6%) Abbot Laboratories [ABT] ... AM Procter & Gamble [PG] ... AM Nasdaq [NDAQ] ... AM United Airlines [UAL] ... PM CSX [CSX] ... PM Crown Castle [CCI] ... PM Kinder Morgan [KMI] ... PM Tesla [TSLA] ... PM |
| Existing Home Sales [Mar] ... 10a |
| Thanks for reading! Don't forget, I'm always eager to hear from you. Reply to this email with your questions, comments, or general feedback, and I'll get back to you as soon as I can. Wishing you big returns on your investments this week, as always! - Michael "The Dork" Taylor P.S. Want My Alerts Delivered To Your Cell Phone? Sign up for mobile alerts and get the latest updates delivered to your cell. Disclaimer © 2022 TheStockDork.com. All rights reserved. This message was sent by TheStockDork.com and may contain commercial elements such as advertising. Read full terms here. |
|
|
|
| | |
|
